What are the main side effects of Lenvatinib?

Lenvatinib (Lenvatinib) is an oral multi-target tyrosine kinase inhibitor commonly used to treat advanced hepatocellular carcinoma (HCC), renal cell carcinoma (RCC) and differentiated thyroid cancer (DTC). However, like all cancer drugs, lenvatinib may cause certain side effects. The following are the main side effects of lenvatinib:

1.Hypertension: One of the most common side effects of lenvatinib is high blood pressure. Because it inhibits the activity of vascular endothelial growth factor receptor (VEGFR), it may cause vasoconstriction and increase in blood pressure. Patients need to monitor their blood pressure regularly during treatment and take appropriate medication to control high blood pressure.

2.Fatigue and weakness: Lenvatinib often causes patients to feel fatigue, which may affect daily life and work. Fatigue is one of the more common side effects of cancer treatment. Patients usually need more rest and pay attention to adjusting their life rhythm.

3.Gastrointestinal discomfort: Lenvatinib may cause gastrointestinal symptoms such as nausea, vomiting, diarrhea, or loss of appetite. These symptoms are usually more common in the early stages of treatment and can be alleviated through dietary modification and medication management.

4.Skin reactions: Skin reactions such as rash and hand-foot syndrome are also common side effects of lenvatinib. Hand-foot syndrome presents with redness, swelling, pain, and even peeling of the palms and soles of the feet. For mild skin reactions, topical treatments may be available, but if symptoms are severe, the medication may need to be suspended or reduced.

5.Abnormal liver function: Lenvatinib may cause liver dysfunction, especially when used to treat hepatocellular carcinoma. It is important to monitor liver function regularly, and if abnormal liver function occurs, treatment may need to be adjusted.

6.Bleeding tendency: Lenvatinib may cause bleeding events, especially in tumor areas with fragile blood vessels. Patients need to be aware of symptoms of abnormal bleeding and use with caution if there is a risk of bleeding.

Overall, the side effects of lenvatinib are generally related to its inhibitory effect on multi-target tyrosine kinases. Although most side effects are manageable, patients should be monitored regularly during use and communicate with their doctor promptly when side effects occur to ensure the safety and effectiveness of the treatment.